Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis

Obesity can be a factor that affects response to anti-TNF drugs. However, studies on patients with ankylosing spondylitis (AS) are rare. We aimed to determine whether obesity affects serum levels of adalimumab (ADL), and immunogenicity and clinical efficacy of the drug in patients with AS. A cross-s...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2017-01, Vol.35 (1), p.145-148
Main Authors: Rosas, José, Llinares-Tello, Francisca, Senabre-Gallego, José Miguel, Barber-Vallés, Xavier, Santos-Soler, Gregorio, Salas-Heredia, Esteban, Pons Bas, Ana, Cano Pérez, Catalina, García-Carrasco, Mario
Format: Article
Language:English
Subjects:
Adalimumab - blood
Adalimumab - therapeutic use
Adult
Antirheumatic Agents - blood
Antirheumatic Agents - therapeutic use
Cross-Sectional Studies
Female
Humans
Male
Middle Aged
Obesity - complications
Spondylitis, Ankylosing - complications
Spondylitis, Ankylosing - drug therapy
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obesity can be a factor that affects response to anti-TNF drugs. However, studies on patients with ankylosing spondylitis (AS) are rare. We aimed to determine whether obesity affects serum levels of adalimumab (ADL), and immunogenicity and clinical efficacy of the drug in patients with AS. A cross-sectional study on 57 patients with axial AS receiving ADL was conducted. They received DMARD per standard of care at their rheumatologist's discretion. Patients' body mass index (BMI) was obtained when ADL treatment began. Clinical response was evaluated using the Spanish versions of the BASDAI index and the ASDAS ESR index. Serum concentrations of free ADL (trough level) and anti-ADL antibodies were measured using Promonitor-ADL and Promonitor Anti-ADL ELISA kits (Progenika Grifols SA, Spain), just prior to the next subcutaneous injection of ADL. Patients with BMI >30 kg/ m2 (obese) as opposed to BMI
ISSN:0392-856X